On September 14, 2026, BioNTech SE and OncoC4 announced updated median overall survival data from the non-pivotal stage 1 of the PRESERVE-003 Phase 3 clinical trial for gotistobart (BNT316/ONC-392) in patients with squamous non-small cell lung cancer. The investigational immunotherapy demonstrated a median overall survival of 18.5 months compared to 10.0 months for standard-of-care docetaxel chemotherapy, representing nearly double the survival benefit (HR: 0.56; nominal p-value=0.0295). This data was presented at the IASLC 2026 World Conference on Lung Cancer and supports gotistobart's potential as a chemotherapy-free monotherapy. BioNTech SE is a global biopharmaceutical company pioneering novel investigative therapies for cancer and other serious diseases.

BioNTech SE terminated the Phase 2 clinical trial (BNT122-01) for autogene cevumeran as an adjuvant monotherapy in patients with ctDNA-positive, surgically resected Stage II or III colorectal cancer. The decision followed a recommendation from the independent Data Safety Monitoring Board, which identified a numerical imbalance in overall survival and concluded that further continuation was unlikely to change efficacy outcomes after the futility boundary was crossed in October 2025. No new safety signals were identified. BioNTech will conduct a thorough analysis of the trial data to inform future development strategies. The Phase 2 IMcode003 trial for autogene cevumeran in pancreatic ductal adenocarcinoma continues as planned. BioNTech SE is a global biopharmaceutical company pioneering novel investigative therapies, particularly mRNA cancer immunotherapies.

On August 27, 2026, the U.S. Food and Drug Administration approved the supplemental Biologics License Application for the 2026-2027 COVID-19 vaccine formula targeting the XFG variant (COMIRNATY ® XFG). The approval covers use in adults ages 65 years and older, as well as individuals ages 5 through 64 with underlying conditions increasing severe outcome risk. Shipping begins immediately to ensure rapid access for the upcoming season. BioNTech SE is a global biopharmaceutical company pioneering novel immunotherapies for cancer and infectious diseases.

BioNTech SE filed a Form 6-K on August 4, 2026, reporting unaudited financial results for the three and six months ended June 30, 2026. The company reported revenues of €105.6 million for the quarter, down from €260.8 million in the prior year period. For the first half of 2026, revenues totaled €223.7 million compared to €443.6 million in the same period of 2025. The company incurred a net loss of €820.8 million for the quarter and €1,352.7 million for the six-month period. Cash and cash equivalents stood at €9,741.0 million as of June 30, 2026. BioNTech SE operates in the biotechnology industry, focusing on next-generation immunotherapies and mRNA-based medicines for cancer and infectious diseases.

BioNTech SE reported second quarter 2026 revenues of €105.6 million, a decline from €260.8 million in the prior year period, driven by lower demand for COVID-19 vaccines. The company announced a revised full-year 2026 revenue guidance range of €1.6–1.9 billion, down from the previous €2.0–2.3 billion estimate, citing softer global vaccine demand and delayed milestone revenues. Adjusted R&D expenses were €477.1 million, while adjusted SG&A expenses stood at €197.8 million. BioNTech initiated six pivotal clinical trials in the first half of 2026, including five for pumitamig and one for elfetabart drozuntecan. The Supervisory Board appointed Guido Oelkers as Chief Executive Officer, effective by February 1, 2027. Additionally, the company repurchased $151.6 million in ADSs during the quarter under a program authorized through May 2027. BioNTech SE is a global biopharmaceutical company pioneering novel investigative therapies for cancer and infectious diseases.